sars-cov-2 3clpro-in-2

SARS-CoV-2 3CLpro-IN-2 is a potent inhibitor of the 3CL protease pair, demonstrating significant research potential for SARS-CoV-2 disease.

SARS-CoV-2 3CLpro-IN-25 (compound 56) effectively inhibits the SARS-CoV-2 3CLpro enzyme, exhibiting an IC50 value of 70 nM, and demonstrates cellular antiviral activity with an EC50 of 3.1 μM.

SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CLpro, demonstrating an IC50 of 21 nM. It also exhibits robust anti-replicase activity against SARS-CoV-2, with an EC50 of 5 nM.

SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is a conformational inhibitor of SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. It demonstrates good cellular permeability, being able to effectively cross the cell membrane following co-incubation with Vero-E6 cells.

3CLPro-IN-3 (Compound A36) is an inhibitor of SARS-CoV-2 3CLpro with an IC50 value of 51.3 nM. It exhibits antiviral activity against human coronaviruses 229E, OC43, and the murine coronavirus MHV.

SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor of SARS-CoV-2 3CLpro, exhibiting an IC50 value of 0.018 μM.

SARS-CoV-2 3CLpro-IN-22 (Compound 17) is an inhibitor of cathepsin L (CTSL) with an IC50 value of 32.5 nM, useful in research related to the SARS-CoV-2 virus.

SARS-CoV-2 3CLpro-IN-23 (CompoundCd3) is a compound isolated from flat lemon (Citrus depressa). It exhibits strong inhibitory activity against the SARS-CoV-2 spike protein with a KD of 0.79 μM. This compound can bind to key amino acid residues, disrupting the formation of the spike protein and h-ACE2 complex.

SARS-CoV-2 3CLpro-IN-20 is a covalent inhibitor of SARS-CoV-2 3CLpro with an IC50 of 0.43 μM and potential antiviral activity.

SARS-CoV-2 3CLpro-IN-21 (Compound D6) is an irreversible, covalent inhibitor of SARS-CoV-2 3CL pro, demonstrating potent inhibition with an IC50 of 0.03 μM. It also exhibits inhibitory activity against SARS-CoV-1 3CL pro with an IC50 of 0.12 μM [1].

PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) .

SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.

Imidazole-D4 is an isotope-labeled variant of imidazole, which is a heterocyclic aromatic compound. Imidazole (T5202) molecules serve as inhibitors for acetylcholinesterase (AChEI) and xanthine oxidase (XO) and have been utilized as corrosion inhibitors. They display a range of biological activities, including antifungal, antitubercular, anti-inflammatory, antioxidant, and analgesic properties. Imidazole (T5202) inhibits platelet microsomes from converting endoperoxides (PGG2 and PGH2) into thromboxane A2. Additionally, imidazole derivatives show inhibitory effects on the SARS-CoV-2 3CLpro enzyme, offering potential for research in Alzheimer’s disease, gout, COVID-19, and thrombotic disorders.

SARS-CoV-2-IN-107 (Compound A7) is an inhibitor of SARS-CoV-2 3CLpro, with an IC50 of 261.3 nM. It inhibits the replication of SARS-CoV-2, exhibiting an EC50 of 11.7 μM. Additionally, SARS-CoV-2-IN-107 demonstrates anti-inflammatory activity in LPS-stimulated RAW264.7 macrophages, with a NO inhibition rate of 68.6%.

SARS-CoV-2 3CLpro-IN-30 (compound 29) is a potent inhibitor of the SARS-CoV-2 3CL protease (SARS-CoV-2 3CLpro), with an IC50 of 0.04 μM and an EC50 of 0.3 μM.

LU9 is an effective 3CLpro inhibitor with an IC50 of 0.34 µM and potential application in SARS-CoV-2 research.

SARS-CoV-2 3CLpro-IN-32 (compound B16) is a potent inhibitor of the SARS-CoV-2 3CLpro enzyme, with an IC50 of 0.109 μM. It also demonstrates antiviral activity against the coronavirus HCoV-OC43, with an EC50 of 1.99 μM.

SARS-CoV-2-IN-71 (compound 8h) is an effective inhibitor of SARS-CoV-2, demonstrating antiviral activity by targeting multiple stages of coronavirus replication. It exhibits its effects by simultaneously acting on 3CLpro and TMPRSS2.

MERS-CoV-IN-2 (compound 3c) is an inhibitor of MERS-CoV 3CLpro with an IC50 of 17 nM. It exhibits antiviral activity against SARS-CoV-2 and MERS-CoV by binding to the active site of the 3CLpro enzyme, specifically at the S4 subsite, thereby inhibiting the enzyme's activity.

SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent inhibitor of the SARS-CoV-2 3CL protease (3CLpro) with an IC50 value of 37.33 nM. It effectively obstructs the cleavage of viral polyproteins and subsequently inhibits the replication of SARS-CoV-2. This compound holds promise for research into SARS-CoV-2 infections.

(±)-Tuaimenal A ((+)-1) is a secondary metabolite and a derivative of Sesamol. It exhibits potent inhibitory activity against SARS-CoV-2 3CLpro, with an IC50 of 33.3 μM. (±)-Tuaimenal A is applicable in research related to SARS-CoV-2 infection.

SARS-CoV-2 3CLpro-IN-33 (Compound 16) is an orally active inhibitor of the SARS-CoV-2 3CL protease, with an IC50 value of 1.5 nM. It demonstrates excellent antiviral activity against SARS-CoV-2 in an HEK293T-AT cell model, with an EC50 value of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 is applicable in COVID-19 infection research.

SARS-CoV-2 3CLpro-IN-34 (Compound 55) is a highly effective non-covalent inhibitor of the SARS-CoV-2 3CLpro protease, with an IC50 of 1.9 μM. It also inhibits the SARS-CoV-1 3CL protease, displaying an IC50 of 3.2 μM, and shows strong selectivity for host cysteine proteases such as cathepsins L/K and calpain. Furthermore, SARS-CoV-2 3CLpro-IN-34 exhibits antiviral activity in SARS-CoV-2 infected cells, with an EC50 of 25 μM, is unaffected by P-gp inhibitors, and does not cause significant cytotoxicity. This compound can be utilized in the study of SARS-CoV-2 infections.

SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is critical for viral replication and serves as an ideal target for intervention. By targeting the SARS-CoV-2 3CL protease, SARS-CoV-2-IN-10 has the potential to facilitate the development of effective antiviral drugs specific to SARS-CoV-2.